In focus · trending topic

HE CTE treatment

1 stories · following the connections

Kannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HE

By Nasdaq OMXFeb 29, 2016, 2:00 PM UTC